CureVac CVAC shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines.
CureVac's stock has been falling Tuesday, down 8.75% to a price of $60.27. The stock's current volume for the day is 709.33 thousand, which is approximately 102.89% of its previous 30-day average volume of 689.40 thousand.
The stock's 50-day moving average was $61.23 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $151.8 and fallen to a low of $43.0.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.